MDT 10013
Alternative Names: MDT-10013Latest Information Update: 22 Mar 2017
At a glance
- Originator Medtronic
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 22 Mar 2017 No recent reports of development identified - Phase-II for Postoperative pain in USA (unspecified route)
- 06 Jun 2016 Medtronic withdraws a phase II trial prior to enrolment in Postoperative pain in USA (NCT02263222)
- 01 Feb 2016 Medtronic completes a phase II trial for Postoperative pain in USA (NCT02077140)